{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:46:31Z","timestamp":1793907991831,"version":"4.8.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40264-020-00962-z","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T12:38:53Z","timestamp":1593607133000},"page":"957-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Neuroprotective Cationic Arginine-Rich Peptides (CARPs): An Assessment of Their Clinical Safety"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-3232","authenticated-orcid":false,"given":"Adam B.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville W.","family":"Knuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fneur.2020.00108","volume":"11","author":"BP Meloni","year":"2020","unstructured":"Meloni BP, Mastaglia FL, Knuckey NW. Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action. Front Neurol. 2020;11:108.","journal-title":"Front Neurol"},{"issue":"8","key":"962_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1517\/13543784.15.8.933","volume":"15","author":"JS Mader","year":"2006","unstructured":"Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs. 2006;15(8):933\u201346.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1\u20133","key":"962_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejphar.2009.08.043","volume":"625","author":"F Schweizer","year":"2009","unstructured":"Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol. 2009;625(1\u20133):190\u20134.","journal-title":"Eur J Pharmacol"},{"key":"962_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fchem.2017.00005","volume":"5","author":"MR Fel\u00edcio","year":"2017","unstructured":"Fel\u00edcio MR, Silva ON, Gon\u00e7alves S, Santos NC, Franco OL. Peptides with dual antimicrobial and anticancer activities. Front Chem. 2017;5:5.","journal-title":"Front Chem"},{"key":"962_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pharmthera.2015.06.002","volume":"153","author":"B Meloni","year":"2015","unstructured":"Meloni B, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther. 2015;153:36\u201354.","journal-title":"Pharmacol Ther"},{"key":"962_CR6","first-page":"993","volume":"35","author":"BP Meloni","year":"2015","unstructured":"Meloni BP, et al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. JCBFM. 2015;35:993\u20131004.","journal-title":"JCBFM."},{"issue":"2\u20133","key":"962_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12017-017-8441-2","volume":"19","author":"BP Meloni","year":"2017","unstructured":"Meloni BP, et al. Assessment of the neuroprotective effects of arginine-rich protamine peptides, poly-arginine peptides (R12-cyclic, R22) and arginine\u2013tryptophan-containing peptides following in vitro excitotoxicity and\/or permanent middle cerebral artery occlusion in rats. Neuromol Med. 2017;19(2\u20133):271\u201385.","journal-title":"Neuromol Med"},{"issue":"3","key":"962_CR8","doi-asserted-by":"publisher","first-page":"e0193884","DOI":"10.1371\/journal.pone.0193884","volume":"13","author":"D Milani","year":"2018","unstructured":"Milani D, et al. Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PLoS One. 2018;13(3):e0193884.","journal-title":"PLoS One"},{"key":"962_CR9","first-page":"2372710","volume":"2016","author":"D Milani","year":"2016","unstructured":"Milani D, Knuckey N, Anderton R, Cross J, Meloni B. The R18 polyarginine peptide is more effective than the TAT-NR2B9c (NA-1) peptide when administered 60 minutes after permanent middle cerebral artery occlusion in the rat. Stroke Res Treat. 2016;2016:2372710.","journal-title":"Stroke Res Treat"},{"key":"962_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neures.2016.09.002","volume":"114","author":"D Milani","year":"2017","unstructured":"Milani D, Cross J, Anderton R, Blacker D, Knuckey N, Meloni B. Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neurosci Res. 2017;114:9\u201315.","journal-title":"Neurosci Res"},{"issue":"2","key":"962_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s13311-019-00809-1","volume":"17","author":"BP Meloni","year":"2020","unstructured":"Meloni BP, et al. Poly-arginine peptide-18 (R18) reduces brain injury and improves functional outcomes in a nonhuman primate stroke model. Neurotherapeutics. 2020;17(2):627\u201334.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"962_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13041-018-0352-0","volume":"11","author":"AB Edwards","year":"2018","unstructured":"Edwards AB, Cross JL, Anderton RA, Knuckey NW, Meloni BP. Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Mol Brain. 2018;11(1):8.","journal-title":"Mol Brain"},{"issue":"11","key":"962_CR13","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/jnr.24315","volume":"96","author":"A Edwards","year":"2018","unstructured":"Edwards AB, Anderton RA, Knuckey NW, Meloni BP. Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy. J Neurosci Res. 2018;96(11):1816\u201326.","journal-title":"J Neurosci Res"},{"issue":"36","key":"962_CR14","doi-asserted-by":"publisher","first-page":"22030","DOI":"10.1074\/jbc.M115.662791","volume":"290","author":"J Marshall","year":"2015","unstructured":"Marshall J, et al. Inhibition of N-methyl-d-aspartate-induced retinal neuronal death by polyarginine peptides is linked to the attenuation of stress-induced hyperpolarization of the inner mitochondrial membrane potential. J Biol Chem. 2015;290(36):22030\u201348.","journal-title":"J Biol Chem"},{"issue":"6","key":"962_CR15","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/mp100223d","volume":"7","author":"D Sarko","year":"2010","unstructured":"Sarko D, et al. The pharmacokinetics of cell-penetrating peptides. Mol Pharm. 2010;7(6):2224\u201331.","journal-title":"Mol Pharm"},{"issue":"10","key":"962_CR16","doi-asserted-by":"publisher","first-page":"e0139652","DOI":"10.1371\/journal.pone.0139652","volume":"10","author":"S Stalmans","year":"2015","unstructured":"Stalmans S, et al. Cell-penetrating peptides selectively cross the blood-brain barrier in vivo. PLoS One. 2015;10(10):e0139652.","journal-title":"PLoS One"},{"issue":"1","key":"962_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.brainres.2007.06.025","volume":"1164","author":"GPH Dietz","year":"2007","unstructured":"Dietz GPH, Dietz B, B\u00e4hr M. Bcl-xL protects cerebellar granule neurons against the late phase, but not against the early phase of glutamate-induced cell death. Brain Res. 2007;1164(1):136\u201341.","journal-title":"Brain Res"},{"issue":"3","key":"962_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1213\/00000539-198503000-00008","volume":"64","author":"JC Horrow","year":"1985","unstructured":"Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64(3):348\u201361.","journal-title":"Anesth Analg"},{"issue":"3","key":"962_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00000542-199009000-00009","volume":"73","author":"DR Morel","year":"1990","unstructured":"Morel DR, Costabella PM, Pittet JF. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Anesthesiology. 1990;73(3):415\u201324.","journal-title":"Anesthesiology"},{"issue":"5","key":"962_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.bja.2018.01.023","volume":"120","author":"C Boer","year":"2018","unstructured":"Boer C, Meesters MI, Veerhoek D, Vonk ABA. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth. 2018;120(5):914\u201327.","journal-title":"Br J Anaesth"},{"issue":"2","key":"962_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0039-6060(96)80157-7","volume":"119","author":"TW Wakefield","year":"1996","unstructured":"Wakefield TW, Hantler CB, Wrobleski SK, Crider BA, Stanley JC. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery. 1996;119(2):123\u20138.","journal-title":"Surgery"},{"issue":"7","key":"962_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1139\/o65-096","volume":"43","author":"H Yoshida","year":"1965","unstructured":"Yoshida H, Fujisawa H, Ohi Y. Influences of protamine on the Na+, K+-dependent ATPase and on the active transport processes of potassium and of l-DOPA into brain slices. Can J Biochem. 1965;43(7):841\u20139.","journal-title":"Can J Biochem"},{"issue":"12","key":"962_CR23","doi-asserted-by":"publisher","first-page":"e8315","DOI":"10.1371\/journal.pone.0008315","volume":"4","author":"PL Diaz-Sylvester","year":"2009","unstructured":"Diaz-Sylvester PL, Copello JA. Voltage-dependent modulation of cardiac ryanodine receptors (RyR2) by protamine. PLoS One. 2009;4(12):e8315.","journal-title":"PLoS One"},{"issue":"12","key":"962_CR24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/BF03012461","volume":"45","author":"H Komatsu","year":"1998","unstructured":"Komatsu H, Enzan K, Matsuura S, Kurosawa S, Mitsuhata H. Systemic hypotensive response to protamine following chronic inhibition of nitric oxide synthase in rats. Can J Anaesth. 1998;45(12):1186\u20139.","journal-title":"Can J Anaesth"},{"issue":"2","key":"962_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF03021822","volume":"53","author":"K Takakura","year":"2006","unstructured":"Takakura K, Mizogami M, Fukuda S. Protamine sulfate causes endothelium-independent vasorelaxation via inducible nitric oxide synthase pathway. Can J Anaesth. 2006;53(2):162\u20137.","journal-title":"Can J Anaesth"},{"issue":"3","key":"962_CR26","first-page":"715","volume":"39","author":"A DeLucia","year":"1993","unstructured":"DeLucia A, et al. Tissue distribution, circulating half-life and excretion of intravenously administered protamine sulfate. ASAIOJ. 1993;39(3):715\u20138.","journal-title":"ASAIOJ."},{"issue":"3","key":"962_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00000539-200203000-00008","volume":"94","author":"J Butterworth","year":"2002","unstructured":"Butterworth J, Lin YA, Prielipp R, Bennett J, James R. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. 2002;94(3):514\u201322.","journal-title":"Anesth Analg"},{"issue":"5","key":"962_CR28","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0003-4975(02)04016-X","volume":"74","author":"J Butterworth","year":"2002","unstructured":"Butterworth J, Lin YA, Prielipp RC, Bennett J, Hammon JW, James RL. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74(5):1589\u201395.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"962_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1742-7843.2008.00274.x","volume":"103","author":"M Nybo","year":"2008","unstructured":"Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103(2):192\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"962_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1208\/s12248-012-9375-0","volume":"14","author":"D Awotwe-Otoo","year":"2012","unstructured":"Awotwe-Otoo D, et al. Physicochemical characterization of complex drug substances: evaluation of structural similarities and differences of protamine sulfate from various sources. AAPS J. 2012;14(3):619\u201326.","journal-title":"AAPS J"},{"issue":"6","key":"962_CR31","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","volume":"137","author":"FD Finkelman","year":"2016","unstructured":"Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137(6):1674\u201380.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"962_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","volume":"12","author":"E Sokolowska","year":"2016","unstructured":"Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol. 2016;12(8):897\u2013909.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"962_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0161-5890(86)90050-7","volume":"23","author":"MC Tobin","year":"1986","unstructured":"Tobin MC, Karns BK, Anselmino LM, Thomas LL. Potentiation of human basophil histamine release by protamine: a new role for a polycation recognition site. Mol Immunol. 1986;23(3):245\u201353.","journal-title":"Mol Immunol"},{"issue":"3","key":"962_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0162-3109(92)90073-L","volume":"24","author":"KR Tainsh","year":"1992","unstructured":"Tainsh KR, Leung Liu W, Yung Lau H, Cohen J, Pearce FL. Mast cell heterogeneity in man: unique functional properties of skin mast cells in response to a range of polycationic stimuli. Immunopharmacology. 1992;24(3):171\u201380.","journal-title":"Immunopharmacology"},{"issue":"1\u20132","key":"962_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF01991461","volume":"11","author":"S Schnitzler","year":"1981","unstructured":"Schnitzler S, Renner H, Pf\u00fcller U. Histamine release from rat mast cells induced by protamine sulfate and polyethylene imine. Agents Actions. 1981;11(1\u20132):73\u20134.","journal-title":"Agents Actions"},{"issue":"1","key":"962_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0049-3848(98)00201-1","volume":"94","author":"Y Byun","year":"1999","unstructured":"Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb Res. 1999;94(1):53\u201361.","journal-title":"Thromb Res"},{"issue":"3","key":"962_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbrc.2015.10.020","volume":"467","author":"T Li","year":"2015","unstructured":"Li T, et al. New synthetic peptide with efficacy for heparin reversal and low toxicity and immunogenicity in comparison to protamine sulfate. Biochem Biophys Res Commun. 2015;467(3):497\u2013502.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"962_CR38","first-page":"116","volume":"68","author":"JF Liang","year":"2003","unstructured":"Liang JF, Zhen L, Chang LC, Yang VC. A less toxic heparin antagonist: low molecular weight protamine. Biochemistry. 2003;68(1):116\u201320.","journal-title":"Biochemistry"},{"issue":"3","key":"962_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1208\/ps030319","volume":"3","author":"L-C Chang","year":"2001","unstructured":"Chang L-C, Wrobleski S, Wakefield TW, Lee LM, Yang VC. Low molecular weight protamine as nontoxic heparin\/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci. 2001;3(3):24\u201331.","journal-title":"AAPS PharmSci"},{"issue":"12","key":"962_CR40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00234-006-0147-3","volume":"48","author":"MH Li","year":"2006","unstructured":"Li MH, et al. Prevention and management of intraprocedural rupture of intracranial aneurysm with detachable coils during embolization. Neuroradiology. 2006;48(12):907\u201315.","journal-title":"Neuroradiology"},{"issue":"6","key":"962_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/jcph.853","volume":"57","author":"JR Guptill","year":"2017","unstructured":"Guptill JR, et al. Phase 1 randomized, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects. J Clin Pharmacol. 2017;57(6):770\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"962_CR42","doi-asserted-by":"publisher","first-page":"e0224870","DOI":"10.1371\/journal.pone.0224870","volume":"14","author":"L Liddle","year":"2019","unstructured":"Liddle L, et al. Poly-arginine-18 peptides do not exacerbate bleeding, or improve functional outcomes following collagenase-induced intracerebral hemorrhage in the rat. PLoS One. 2019;14(11):e0224870.","journal-title":"PLoS One"},{"issue":"9","key":"962_CR43","first-page":"539","volume":"17","author":"J Miklosz","year":"2019","unstructured":"Miklosz J, et al. The inhibitory effect of protamine on platelets is attenuated by heparin without inducing thrombocytopenia in rodents. Drugs. 2019;17(9):539\u201357.","journal-title":"Drugs."},{"issue":"4","key":"962_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/MBC.0b013e328343f93f","volume":"22","author":"MH Coggin","year":"2011","unstructured":"Coggin MH, Ahl R, Roland A, Beck D, Brecher AS. Protamine sulfate stimulates degradation of factor Xa and the factor Xa-antithrombin complex. Blood Coagul Fibrinolysis. 2011;22(4):247\u201353.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"962_CR45","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2009-05-222109","volume":"114","author":"F Ni Ainle","year":"2009","unstructured":"Ni Ainle F, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114(8):1658\u201365.","journal-title":"Blood"},{"issue":"1","key":"962_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejvs.2008.01.021","volume":"36","author":"D Dellagrammaticas","year":"2008","unstructured":"Dellagrammaticas D, Lewis SC, Gough MJ, GALA Trial Collaborators. Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg. 2008;36(1):41\u20134.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"962_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jvs.2009.10.078","volume":"51","author":"DH Stone","year":"2010","unstructured":"Stone DH, et al. Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke. J Vasc Surg. 2010;51(3):559.","journal-title":"J Vasc Surg"},{"issue":"5","key":"962_CR48","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00268-013-2347-4","volume":"38","author":"F Mazzalai","year":"2014","unstructured":"Mazzalai F, Piatto G, Toniato A, Lorenzetti R, Baracchini C, Ballotta E. Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events. World J Surg. 2014;38(5):1227\u2013322.","journal-title":"World J Surg"},{"issue":"1","key":"962_CR49","first-page":"1","volume":"21","author":"M Sumner-Smith","year":"1995","unstructured":"Sumner-Smith M, Zheng Y, Zhang YP, Twist EM, Climie SC. Antiherpetic activities of N-alpha-acetyl-nona-d-arginine amide acetate. Drugs Exp Clin Res. 1995;21(1):1\u20136.","journal-title":"Drugs Exp Clin Res"},{"issue":"8","key":"962_CR50","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.186.8.1395","volume":"186","author":"BJ Doranz","year":"1997","unstructured":"Doranz BJ, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997;186(8):1395\u2013400.","journal-title":"J Exp Med"},{"issue":"6","key":"962_CR51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/08892220151126508","volume":"17","author":"BJ Doranz","year":"2001","unstructured":"Doranz BJ, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses. 2001;17(6):475\u201386.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"962_CR52","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1021\/acschemneuro.9b00458","volume":"10","author":"T Zhang","year":"2019","unstructured":"Zhang T, Gering I, Kutzsche J, Nagel-Steger L, Willbold D. Toward the mode of action of the clinical stage all-D-enantiomeric peptide RD2 on A\u03b242 aggregation. ACS Chem Neurosci. 2019;10(12):4800\u20139.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"962_CR53","doi-asserted-by":"publisher","first-page":"16275","DOI":"10.1038\/s41598-017-16565-1","volume":"7","author":"T Van Groen","year":"2017","unstructured":"Van Groen T, et al. The A\u03b2 oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep. 2017;7(1):16275.","journal-title":"Sci Rep"},{"issue":"3","key":"962_CR54","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s12035-018-1209-3","volume":"56","author":"S Schemmert","year":"2019","unstructured":"Schemmert S, et al. A\u03b2 oligomer elimination restores cognition in transgenic Alzheimer\u2019s mice with full-blown pathology. Mol Neurobiol. 2019;56(3):2211\u201323.","journal-title":"Mol Neurobiol"},{"key":"962_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2016.04.016","volume":"89","author":"LHE Leithold","year":"2016","unstructured":"Leithold LHE, et al. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer\u2019s disease. Eur J Pharm Sci. 2016;89:31\u20138.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"962_CR56","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1038\/s41598-019-41993-6","volume":"9","author":"A Elfgen","year":"2019","unstructured":"Elfgen A, et al. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-\u03b2 oligomers. Sci Rep. 2019;9(1):5715.","journal-title":"Sci Rep"},{"issue":"12","key":"962_CR57","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/molecules24122237","volume":"24","author":"D Willbold","year":"2019","unstructured":"Willbold D, Kutzsche J. Do we need anti-prion compounds to treat Alzheimer\u2019s disease? Molecules. 2019;24(12):2237\u201347.","journal-title":"Molecules."},{"issue":"1","key":"962_CR58","doi-asserted-by":"crossref","first-page":"e12001","DOI":"10.1002\/trc2.12001","volume":"6","author":"J Kutzsche","year":"2020","unstructured":"Kutzsche J, et al. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: a single and multiple ascending dose phase I study. Alzheimer\u2019s Dement Transl Res Clin Interv. 2020;6(1):e12001.","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"issue":"5594","key":"962_CR59","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1126\/science.1072873","volume":"298","author":"M Aarts","year":"2002","unstructured":"Aarts M, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298(5594):846\u201350.","journal-title":"Science"},{"issue":"9","key":"962_CR60","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1161\/STROKEAHA.107.506048","volume":"39","author":"HS Sun","year":"2008","unstructured":"Sun HS, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke. 2008;39(9):2544\u201353.","journal-title":"Stroke"},{"issue":"11","key":"962_CR61","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1161\/STROKEAHA.111.618801","volume":"42","author":"BT Br\u00e5tane","year":"2011","unstructured":"Br\u00e5tane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke. 2011;42(11):3265\u201370.","journal-title":"Stroke"},{"issue":"3","key":"962_CR62","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/0271678X15612099","volume":"36","author":"LM Teves","year":"2016","unstructured":"Teves LM, Cui H, Tymianski M. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J Cereb Blood Flow Metab. 2016;36(3):555\u201361.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7388","key":"962_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature10841","volume":"483","author":"FJ Cook","year":"2012","unstructured":"Cook FJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483(7388):213\u20137.","journal-title":"Nature"},{"issue":"11","key":"962_CR64","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1474-4422(12)70225-9","volume":"11","author":"MD Hill","year":"2012","unstructured":"Hill MD, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11(11):942\u201350.","journal-title":"Lancet Neurol"},{"key":"962_CR65","unstructured":"Tymianski M, Garman J. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory. EP2229185A2. 2008."},{"issue":"10227","key":"962_CR66","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill MD, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395(10227):878\u201387.","journal-title":"Lancet"},{"issue":"10227","key":"962_CR67","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(20)30316-0","volume":"395","author":"GJ Hankey","year":"2020","unstructured":"Hankey GJ. Nerinetide before reperfusion in acute ischaemic stroke: d\u00e9j\u00e0 vu or new insights? Lancet. 2020;395(10227):843\u20134.","journal-title":"Lancet"},{"issue":"3","key":"962_CR68","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ijcard.2012.03.071","volume":"167","author":"JD Rich","year":"2013","unstructured":"Rich JD, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013;167(3):669\u201376.","journal-title":"Int J Cardiol"},{"issue":"2","key":"962_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/ALN.0b013e31825e6eb3","volume":"117","author":"P Nagele","year":"2012","unstructured":"Nagele P, Pal S, Brown F, Blood J, Miller JP, Johnston J. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia. Anesthesiology. 2012;117(2):321\u20138.","journal-title":"Anesthesiology"},{"issue":"3","key":"962_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0024-3205(02)02245-2","volume":"72","author":"MK Pugsley","year":"2002","unstructured":"Pugsley MK, Kalra V, Froebel-Wilson S. Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle. Life Sci. 2002;72(3):293\u2013305.","journal-title":"Life Sci"},{"issue":"2","key":"962_CR71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/1046-5928(90)90005-J","volume":"1","author":"JA Hoffman","year":"1990","unstructured":"Hoffman JA, Chance RE, Johnson MG. Purification andanalysis of the major components of chum salmon protaminecontained in insulin formulations using high-performanceliquid chromatography. Protein Expr Purif. 1990;1(2):127\u201335.","journal-title":"Protein Expr Purif."},{"issue":"4","key":"962_CR72","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0091-6749(90)90189-B","volume":"85","author":"JM Weiler","year":"1990","unstructured":"Weiler JM, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990;85(4):713\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"962_CR73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10840-009-9364-0","volume":"25","author":"K Chilukuri","year":"2009","unstructured":"Chilukuri K, et al. Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of arterial fibrillation. J Interv Card Electrophysiol. 2009;25(3):175\u201381.","journal-title":"J Interv Card Electrophysiol."},{"issue":"2","key":"962_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10840-015-9989-0","volume":"43","author":"KM Gurses","year":"2015","unstructured":"Gurses KM, et al. Safety and efficacy outcomes of protamineadministration for heparin reversal following cryoballoon-based pulmonary vein isolation. J Interv Card Electrophysiol. 2015;43(2):161\u20137.","journal-title":"J Interv Card Electrophysiol."},{"issue":"2","key":"962_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/ki.1982.144","volume":"22","author":"VM Vehaskari","year":"1982","unstructured":"Vehaskari VM, Root ER, Germuth FG, Robson AM. Glomerular charge and urinary protein excretion: efects of systemicand intrarenal polycation infusion in the rat. Kidney Int. 1982;22(2):127\u201335.","journal-title":"Kidney Int."},{"issue":"2","key":"962_CR76","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-8993(87)90705-0","volume":"409","author":"LJ Strausbaugh","year":"1987","unstructured":"Strausbaugh LJ. Intracarotid infusions of protamine sulfate disruptthe blood-brain barrier of rabbits. Brain Res. 1987;409(2):221\u20136.","journal-title":"Brain Res."},{"issue":"6","key":"962_CR77","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0022-5223(96)70227-1","volume":"111","author":"GV Raikar","year":"1996","unstructured":"Raikar GV, Hisamochi K, Raikar BL, Schaf HV. Nitric oxideinhibition attenuates systemic hypotension produced by protamine. J Thorac Cardiovasc Surg. 1996;111(6):1240\u20136 (discussion1246\u20137).","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"5","key":"962_CR78","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/jvet.2000.9136","volume":"29","author":"MR Morgan","year":"2000","unstructured":"Morgan MR, Monnet E, Gaynor JS. The effect of differingrates and injection sites on the amount of protamine deliveredbefore detection of hemodynamic alterations in dogs. Vet Surg. 2000;29(5):442\u20138.","journal-title":"Vet Surg."},{"issue":"6","key":"962_CR79","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/00000542-200106000-00016","volume":"94","author":"T Oguchi","year":"2001","unstructured":"Oguchi T, Doursout MF, Kashimoto S, Yan Liang Y, Hartley CJ, Chelly JE. Role of heparin and nitric oxide in the cardiac and regional hemodynamic properties of protamine in conscious chronically instrumented dogs. Anesthesiology. 2001;94(6):1016.","journal-title":"Anesthesiology."},{"issue":"4","key":"962_CR80","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3171\/2014.4.JNS132187","volume":"121","author":"SR Satti","year":"2014","unstructured":"Satti SR. Vessel perforation during withdrawal of TrevoProVue stent retriever during mechanical thrombectomy for acute ischemic stroke. J Neurosurg. 2014;121(4):995\u20138.","journal-title":"J Neurosurg."},{"issue":"10","key":"962_CR81","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1002\/phar.1997","volume":"37","author":"GV Fontaine","year":"2017","unstructured":"Fontaine GV, Smith SM. Alteplase for acute ischemic stroke after heparin reversal with protamine: a case report and review. Pharmacotherapy. 2017;37(10):e103\u2013e106106.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"962_CR82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MBC.0000000000000569","volume":"28","author":"C Guevara","year":"2017","unstructured":"Guevara C, et al. Acute ischemic stroke after cardiac catheterization: the protamine low-dose recombinant tissue plasminogen activator pathway. Blood Coagul Fibrinolysis. 2017;28(3):261\u20133.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"962_CR83","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1097\/MJT.0000000000000634","volume":"25","author":"O Danoun","year":"2018","unstructured":"Danoun O, Sachar P, Rajamani K. Thrombolysis for acute ischemic stroke after protamine reversal of heparin. Am J Ther. 2018;25(5):e552\u2013e55454.","journal-title":"Am J Ther"},{"issue":"6","key":"962_CR84","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/NRL.0000000000000204","volume":"23","author":"DS Warner","year":"2018","unstructured":"Warner DS, et al. Thrombolysis after protamine reversal of heparin for acute ischemic stroke after cardiac catheterization: case report and literature review. Neurologist. 2018;23(6):194\u20136.","journal-title":"Neurologist"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00962-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00962-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00962-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:07:31Z","timestamp":1696320451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00962-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00962-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"1 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Neville W. Knuckey and Bruno P. Meloni are named inventors on several patents for the use of CARPs as therapeutic agents. In addition, Neville W. Knuckey, Bruno P. Meloni and Adam B. Edwards are shareholders in Argenica Therapeutics, which is a company developing R18 as a stroke therapeutic. Frank L. Mastaglia has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}